The primary patent for Vyvanse (lisdexamfetamine dimesylate) is set to expire in December 2023 [1]. This expiration date pertains to the formulation patent [2].
What happens after the Vyvanse patent expires?
Following the patent expiration, generic versions of Vyvanse are expected to become available. This typically leads to lower prices for the medication [3]. The availability of generics can significantly impact the market for the branded drug.
Are there other patents protecting Vyvanse?
Beyond the main formulation patent, there are other patents associated with Vyvanse, including those related to its manufacturing process and specific uses [2]. However, the December 2023 expiration date is a key milestone for market entry of generics. Some sources indicate that certain patents may extend further, potentially into 2025 [1].
What is lisdexamfetamine dimesylate?
Lisdexamfetamine dimesylate is the active ingredient in Vyvanse. It is a stimulant medication used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in both children and adults [4]. The drug works by affecting chemicals in the brain that are thought to be related to hyperactivity and impulsivity [5].
When did Vyvanse first receive FDA approval?
Vyvanse was first approved by the U.S. Food and Drug Administration (FDA) in 2007 [4].
How does Vyvanse work?
Vyvanse is a prodrug, meaning it is converted into its active form, dextroamphetamine, in the body. This conversion process is thought to provide a smoother, longer-lasting effect compared to immediate-release amphetamines [5].
Who manufactures Vyvanse?
Vyvanse is manufactured by Shire, a Takeda company [4].
What are the alternatives to Vyvanse for ADHD?
Alternatives to Vyvanse for ADHD treatment include other stimulant medications such as Adderall XR, Ritalin LA, and Concerta, as well as non-stimulant options like Strattera and Intuniv [5].
What are the side effects of Vyvanse?
Common side effects of Vyvanse can include decreased appetite, dry mouth, trouble sleeping, weight loss, and increased blood pressure [5].
Can biosimilars be developed for Vyvanse?
Vyvanse is a small molecule drug, not a biologic. Therefore, biosimilars, which are similar to generics but for biologic drugs, are not applicable. Generic versions of small molecule drugs like Vyvanse are what enter the market after patent expiration [3].
How can I find out about specific Vyvanse patent details?
Information on drug patents, including expiration dates and any ongoing litigation, can often be found through specialized databases and resources like DrugPatentWatch.com [1].
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/drugs/vyvanse-lisdexamfetamine-dimesylate
[3] https://www.drugpatentwatch.com/
[4] https://www.vyvanse.com/
[5] https://www.webmd.com/drugs/2/205765/vyvanse-oral